Loma Linda University Health now offers a newly FDA-approved HIV prevention medication that only needs to be administered twice a year — a major advancement for those at risk of HIV infection who prefer an alternative to daily oral pre-exposure prophylaxis (PrEP).
Jennifer Veltman, MD, chief of infectious diseases at Loma Linda University Health, says this breakthrough treatment is delivered as a subcutaneous injection in the abdomen and offers a new level of convenience and effectiveness.
“This new option gives people more control over their HIV prevention,” Veltman said. “With just two shots a year, it simplifies protection in a way we haven’t seen before. That’s especially huge for public health in our region.”
Read: Alarming rates of HIV in Inland Empire emphasize need for testing for all
The injectable medication, lenacapavir, was recently approved by the FDA based on results from multiple global clinical trials. Loma Linda University Health served as a study site for the clinical trials that led to the approval of this innovative HIV prevention treatment. By helping to enroll and monitor participants, LLUH contributed to the broader research efforts evaluating the safety and effectiveness of lenacapavir. Veltman and the infectious disease team were actively involved in supporting the trial locally, reflecting the institution’s dedication to advancing HIV prevention through research and patient-centered care.
Lenacapavir works by targeting the HIV capsid, a protein shell that protects the virus's genetic material and is essential for its replication cycle. By disrupting the capsid's function, the drug prevents HIV from multiplying and spreading within the body. Its long-acting formulation allows the medication to remain active in the body for months, offering sustained protection with just two injections per year.
“Some patients struggle with the daily commitment of a pill. This injection removes that barrier while offering superior protection,” Veltman said.
The new option is expected to increase PrEP adherence and reach more people in vulnerable communities who may face challenges with taking daily medication.
Loma Linda University Health’s infectious disease specialists are now offering consultations for patients interested in lenacapavir for HIV prevention.
“We’re excited to offer this to our community,” Veltman said. “It's empowering to have more tools in our toolkit to end the HIV epidemic.”
Our infectious disease experts are here to help you get the care you need. Schedule an appointment today to learn about PrEP options.